4BIO Capital intends to take gene and cell therapies mainstream
Category: #health  By Paroma Bhattacharya  Date: 2019-09-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

4BIO Capital intends to take gene and cell therapies mainstream

The venture capitalist firm has secured an investment of $50 million and is expecting to gather an investment of up to $150 million till 2020.

4BIO Capital, a London-based firm investing in Public Equities in Life Sciences and Venture Capital, has made headlines for raising $50 million (€45 million) to finance advanced therapy startups. The leading venture capital firm intends to invest the money, with an additional $100 million which it expects to add by the final close, into those firms that are focused on extending the use of improved therapies to critical diseases such as rheumatoid arthritis and diabetes.

As per reports, 4BIO has secured the $50 million commitment, involving a cornerstone investment from Children’s Minnesota, a U.S pediatric hospital, for its next advanced therapy VC fund accompanied by the previous successful investments in companies like Orchard Therapeutics. Currently, the firm aims to improve the advanced therapy sector and wants to demonstrate efficiency in critical diseases. 

Speaking on the move, Dmitry Kuzmin, Managing Partner, 4BIO, said that the company is focused on evolving advanced therapies from their historical stage of monogenic genetic disorders and super-rare diseases to a larger, more publicly significant indications where the firm openly has thousands of patients. 

Reportedly, a string of milestone gene and cell therapy approvals have turned the firm’s perceptions, allowing it to research on major diseases and appeal the investment needed to bankroll their elaborate strategy. 

According to Kuzmin, the company is delighted by the level of interest it has gained and is now witnessing a considerable growth of interest in Institutional investors.

Moreover, that interest has resulted in commitments of above $50 million. The company eventually expects to have an investment of $150 million until it holds the final close of the fund in the Q3&4 of 2020.

Additionally, the company will put the investment in developers of gene and cell therapies, targeted treatments, the microbiome and RNA-based candidates, with a quarter of the money going to the firms created by 4BIO itself.

Source Credit: https://www.fiercebiotech.com/biotech/4bio-raises-vc-fund-to-take-cell-and-gene-therapies-mainstream



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program
Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program
By Paroma Bhattacharya

Type 2 diabetes is a prevailing disease in which cells become unresponsive to insulin while gradually increasing blood sugar. With growing cases of Type 2 diabetes worldwide, pharmaceutical companies are now focusing o...

Poxel commences its Phase 1b trial for NASH drug candidate, PXL065
Poxel commences its Phase 1b trial for NASH drug candidate, PXL065
By Paroma Bhattacharya

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by the buildup of fat in the liver mostly with people who drink little or no alcohol. With growing cases of NASH prevailing worldwide, pharmaceutical com...

Flipkart extents delivery reach by 80% to cover more pincodes in India
Flipkart extents delivery reach by 80% to cover more pincodes in India
By Paroma Bhattacharya

  • The e-commerce site has managed to grow its reach to an estimate of 19,200 PIN codes from its prior 10,660 last year for the delivery of huge appliances.